Literature DB >> 4060841

Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine.

A J Georges, F Tible, D M Meunier, J P Gonzalez, A M Beraud, N R Sissoko-Dybdahl, S Abdul-Wahid, B Fritzell, M Girard, M C Georges-Courbot.   

Abstract

Samples of the new, stabilized 17D virus vaccine from Pasteur Vaccins, France were stored for up to six months at +10 +/- 2 degrees C in the hospital of Bouar, Central African Republic. Each month during this study, the vaccine ampoules were put into an ice box without ice and taken into the field to be used as part of a vaccination programme. No significant loss of infectious virus titre was observed under these conditions. Efficacy of the vaccine was determined from percent seroconversions in vaccinated children. No loss of efficacy of the vaccine was observed after five months storage at +10 degrees C and five trips in the field, confirming the high heat stability of the new vaccine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4060841     DOI: 10.1016/s0264-410x(85)90182-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.

Authors: 
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-09       Impact factor: 2.743

2.  17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.

Authors:  Ana Carolina Campi-Azevedo; Luiza Pacheco de Araújo-Porto; Maria Luiza-Silva; Maurício Azevedo Batista; Marina Angela Martins; Renato Sathler-Avelar; Denise da Silveira-Lemos; Luiz Antonio Bastos Camacho; Reinaldo de Menezes Martins; Maria de Lourdes de Sousa Maia; Roberto Henrique Guedes Farias; Marcos da Silva Freire; Ricardo Galler; Akira Homma; José Geraldo Leite Ribeiro; Jandira Aparecida Campos Lemos; Maria Auxiliadora-Martins; Iramaya Rodrigues Caldas; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.